Phospho-MEK1/2 (Ser218+Ser222/Ser222+Ser226) Antibody | Affinity Biosciences LTD|亲科生物官网

产品:	磷酸化 MEK1/2 (Ser218+Ser222/Ser222+Ser226) 抗体
货号:	AF8035
描述:	Rabbit polyclonal antibody to Phospho-MEK1/2 (Ser218+Ser222/Ser222+Ser226)
应用:	WB IHC IF/ICC
反应:	Human, Mouse, Rat
预测:	Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
分子量:	45kDa; 43kD,44kD(Calculated).
蛋白号:	Q02750 \| P36507
RRID:	AB_2840098

浏览相似产品>>

阻断肽(封闭肽)是特异性结合目标抗体和阻断抗体结合的多肽。这些多肽包含抗体识别的抗原表位。与阻断肽结合的抗体不再与靶蛋白上的表位结合。例如，在免疫印迹(WB)和免疫组化(IHC)中，通过比较被阻断抗体和未阻断抗体的染色，可以看到哪种染色是特异性的。

规格	价格	库存
50ul	RMB¥ 1500	现货
100ul	RMB¥ 2800	现货
200ul	RMB¥ 3800	现货

货期: 当天发货

联系销售

实验方案

产品描述

来源:

Rabbit

应用:

WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:

Human,Mouse,Rat

预测:

Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)

克隆:

Polyclonal

特异性:

Phospho-MEK1/2 (Ser218+Ser222/Ser222+Ser226) Antibody detects endogenous levels of MEK1/2 only when phosphorylated at S218+S222(MEK1)/S222+S226(MEK2).

RRID:

AB_2840098
引用格式: Affinity Biosciences Cat# AF8035, RRID:AB_2840098.

偶联:

Unconjugated.

纯化:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

别名:

展开/折叠

Dual specificity mitogen activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; MAP kinase kinase 1; MAP kinase/Erk kinase 1; MAP2K1; MAPK/ERK kinase 1; MAPKK 1; MAPKK1; MEK 1; Mek1; MEKK1; Mitogen activated protein kinase kinase 1; MKK 1; MKK1; MP2K1_HUMAN; PRKMK1; Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1); Protein kinase mitogen activated, kinase 1; Cardiofaciocutaneous syndrome; CFC syndrome; CFC4; Dual specificity mitogen activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 2; FLJ26075; MAP kinase kinase 2; map2k2; MAPK / ERK kinase 2; MAPK/ERK kinase 2; MAPKK 2; MAPKK2; MEK 2; MEK2; Microtubule associated protein kinase kinase 2; Mitogen activated protein kinase kinase 2; Mitogen activated protein kinase kinase 2 p45; MKK 2; MKK2; MP2K2_HUMAN; OTTHUMP00000165826; OTTHUMP00000165827; PRKMK 2; PRKMK2;

抗原和靶标

免疫原:

Uniprot:

Q02750(MP2K1_HUMAN) >>Visit HPA database.

P36507(MP2K2_HUMAN) >>Visit HPA database.

基因/基因ID:

MAP2K1(5604) | MAP2K2(5605)

表达:

Q02750 MP2K1_HUMAN:

Widely expressed, with extremely low levels in brain.

序列:

Q02750 MP2K1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV

P36507 MP2K2_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species

Results

Score

Pig

100

Horse

100

Bovine

100

Sheep

100

Dog

100

Xenopus

100

Zebrafish

100

Chicken

100

Rabbit

100

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - Q02750/P36507 作为底物

P36507
Q02750

Site	PTM Type	Enzyme	Source
M1	Acetylation		Uniprot
K6	Ubiquitination		Uniprot
T13	Acetylation		Uniprot
S23	Phosphorylation		Uniprot
T25	Phosphorylation		Uniprot
S26	Phosphorylation	P36507 (MAP2K2)	Uniprot
S30	Phosphorylation		Uniprot
K40	Ubiquitination		Uniprot
K51	Ubiquitination		Uniprot
T59	Phosphorylation	O14757 (CHEK1)	Uniprot
K61	Ubiquitination		Uniprot
K63	Ubiquitination		Uniprot
K68	Ubiquitination		Uniprot
K88	Ubiquitination		Uniprot
S94	Phosphorylation		Uniprot
K101	Ubiquitination		Uniprot
K108	Sumoylation		Uniprot
K108	Ubiquitination		Uniprot
K163	Ubiquitination		Uniprot
K196	Ubiquitination		Uniprot
S198	Phosphorylation		Uniprot
K209	Ubiquitination		Uniprot
S216	Phosphorylation		Uniprot
S222	Acetylation		Uniprot
S222	Phosphorylation	P15056 (BRAF) , P41279 (MAP3K8) , O15530 (PDPK1) , P53350 (PLK1)	Uniprot
S226	Acetylation		Uniprot
S226	Phosphorylation	O15530 (PDPK1) , P53350 (PLK1) , P15056 (BRAF) , P41279 (MAP3K8) , P36507 (MAP2K2)	Uniprot
T230	Phosphorylation		Uniprot
S293	Phosphorylation		Uniprot
S295	Phosphorylation		Uniprot
S306	Phosphorylation		Uniprot
S312	Phosphorylation		Uniprot
K352	Ubiquitination		Uniprot
K361	Ubiquitination		Uniprot
K370	Ubiquitination		Uniprot
S372	Phosphorylation		Uniprot
K385	Ubiquitination		Uniprot
T394	Phosphorylation		Uniprot
T396	Phosphorylation	P36507 (MAP2K2)	Uniprot
T398	Phosphorylation		Uniprot

Site	PTM Type	Enzyme	Source
T23	Phosphorylation		Uniprot
S24	Phosphorylation	Q6VAB6 (KSR2)	Uniprot
S25	Phosphorylation		Uniprot
K36	Ubiquitination		Uniprot
T55	Phosphorylation	O14757 (CHEK1)	Uniprot
K57	Ubiquitination		Uniprot
K64	Ubiquitination		Uniprot
K70	Ubiquitination		Uniprot
S72	Phosphorylation	Q6VAB6 (KSR2)	Uniprot
K88	Ubiquitination		Uniprot
K97	Ubiquitination		Uniprot
K104	Sumoylation		Uniprot
K104	Ubiquitination		Uniprot
K168	Ubiquitination		Uniprot
K175	Acetylation		Uniprot
K175	Ubiquitination		Uniprot
K192	Ubiquitination		Uniprot
S194	Phosphorylation		Uniprot
K205	Ubiquitination		Uniprot
S212	Phosphorylation		Uniprot
S218	Phosphorylation	P53350 (PLK1) , O15530 (PDPK1) , P15056 (BRAF) , P41279 (MAP3K8) , Q5TCX8 (MAP3K21) , P00540 (MOS) , Q13233 (MAP3K1) , P10398 (ARAF) , P04049 (RAF1)	Uniprot
S222	Phosphorylation	Q5TCX8 (MAP3K21) , P10398 (ARAF) , Q13233 (MAP3K1) , P53350 (PLK1) , O15530 (PDPK1) , P00540 (MOS) , P04049 (RAF1) , P15056 (BRAF) , P41279 (MAP3K8)	Uniprot
T226	Phosphorylation		Uniprot
S231	Phosphorylation		Uniprot
S244	Phosphorylation	P41279 (MAP3K8)	Uniprot
S248	Phosphorylation	P41279 (MAP3K8)	Uniprot
T286	Phosphorylation	Q00535 (CDK5) , P06493 (CDK1) , P27361 (MAPK3) , P28482 (MAPK1)	Uniprot
T292	Phosphorylation	P06493 (CDK1) , P27361 (MAPK3) , Q00535 (CDK5) , P28482 (MAPK1)	Uniprot
S298	Phosphorylation	Q13153 (PAK1) , Q02750 (MAP2K1) , O75914 (PAK3)	Uniprot
S299	Phosphorylation		Uniprot
Y300	Phosphorylation	Q02750 (MAP2K1)	Uniprot
K344	Ubiquitination		Uniprot
K353	Ubiquitination		Uniprot
K362	Acetylation		Uniprot
S385	Phosphorylation		Uniprot
T386	Phosphorylation	P28482 (MAPK1) , P27361 (MAPK3)	Uniprot
T388	Phosphorylation		Uniprot

翻译修饰 - Q02750/P36507 作为激酶

P36507
Q02750

Substrate	Site	Source
P05787 (KRT8)	S74	Uniprot
P27361 (MAPK3)	T202	Uniprot
P27361 (MAPK3)	Y204	Uniprot
P28482 (MAPK1)	T185	Uniprot
P28482 (MAPK1)	Y187	Uniprot
P36507 (MAP2K2)	S26	Uniprot
P36507 (MAP2K2)	S226	Uniprot
P36507 (MAP2K2)	T396	Uniprot
P55211-1 (CASP9)	T125	Uniprot

Substrate	Site	Source
O75676-1 (RPS6KA4)	S196	Uniprot
O75676-1 (RPS6KA4)	S343	Uniprot
O75676-1 (RPS6KA4)	S347	Uniprot
O75676-1 (RPS6KA4)	S360	Uniprot
O75676-2 (RPS6KA4)	T562	Uniprot
O75676-1 (RPS6KA4)	T568	Uniprot
P04049 (RAF1)	S338	Uniprot
P05787 (KRT8)	S74	Uniprot
P15172 (MYOD1)	Y156	Uniprot
P17542 (TAL1)	S122	Uniprot
P27361 (MAPK3)	T202	Uniprot
P27361 (MAPK3)	Y204	Uniprot
P27361 (MAPK3)	T207	Uniprot
P27361 (MAPK3)	Y210	Uniprot
P28482 (MAPK1)	T185	Uniprot
P28482 (MAPK1)	Y187	Uniprot
P32121 (ARRB2)	T382	Uniprot
P35568 (IRS1)	S307	Uniprot
P37231 (PPARG)	S112	Uniprot
P49841 (GSK3B)	Y216	Uniprot
P55211-1 (CASP9)	T125	Uniprot
Q00613 (HSF1)	S326	Uniprot
Q02750 (MAP2K1)	S298	Uniprot
Q02750 (MAP2K1)	Y300	Uniprot
Q02750-1 (MAP2K1)	S304	Uniprot

研究背景

Q02750_MP2K1_HUMAN
P36507_MP2K2_HUMAN

功能:

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.

翻译修饰:

Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (BRAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK.

Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.

细胞定位:

Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome. Cytoplasm>Cytoskeleton>Microtubule organizing center>Spindle pole body. Cytoplasm. Nucleus. Membrane>Peripheral membrane protein.
Note: Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111). Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742).

组织特异性:

Widely expressed, with extremely low levels in brain.

亚基结构:

Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3/ERK1 and RGS14 (By similarity). Forms a heterodimer with MAP2K2/MEK2 (By similarity). Forms heterodimers with KSR2 which further dimerize to form tetramers (By similarity). Interacts with KSR1 or KSR2 and BRAF; the interaction with KSR1 or KSR2 mediates KSR1-BRAF or KSR2-BRAF dimerization. Interacts with ARBB2, LAMTOR3, MAPK1/ERK2 and RAF1 (By similarity). Interacts with MORG1 (By similarity). Interacts with PPARG. Interacts with isoform 1 of VRK2. Interacts with SGK1. Interacts with BIRC6/bruce. Interacts with KAT7; the interaction promotes KAT7 phosphorylation (By similarity).

(Microbial infection) Interacts with Yersinia yopJ.

蛋白家族:

The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1.

Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.

功能:

Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation.

翻译修饰:

MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1). Phosphorylated by MAP2K1/MEK1 (By similarity).

Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.

细胞定位:

Cytoplasm. Membrane>Peripheral membrane protein.
Note: Membrane localization is probably regulated by its interaction with KSR1.

亚基结构:

Interacts with MORG1 (By similarity). Interacts with SGK1. Interacts with KSR1. Interacts with KSR1 and BRAF; the interaction with KSR1 mediates KSR1-BRAF dimerization. Interacts with GLS.

蛋白家族:

Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.

研究领域

· Cellular Processes > Cell growth and death > Oocyte meiosis. (View pathway)

· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Gap junction. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Glioma. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis. (View pathway)

· Organismal Systems > Nervous system > Long-term potentiation.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Melanogenesis.

· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit. Cell Death & Disease, 2021 (PubMed: 34006845) [IF=9.0]

Application: WB Species: Human Sample: AML cells

Fig. 5 CD27-AS1 regulates MAPK signaling pathway in the AML cell lines. a HL-60 and KG-1 cells were infected with LV-CD27-AS1 and LV-CD27- AS1-Sh1. Protein levels of P38, p-P38, JNK, p-JNK, p-C-raf, p-MEK1/2, ERK, and p-ERK were detected using western blotting. b Densitometry analysis of protein levels in both cells was performed. c U0126, a MEK1/2 inhibitor, was used to treat the AML cells with CD27-AS1 upregulation. Relative protein levels of p-ERK and ERK were measured using western blotting. d CCK-8 assay was performed to check cell viability. N = 3. Data were shown as means ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

2). Serum proteomics analysis based on label-free revealed the protective effect of Chinese herbal formula Gu-Ben-Fang-Xiao. BIOMEDICINE & PHARMACOTHERAPY, 2019 (PubMed: 31520916) [IF=7.5]

Application: WB Species: mouse Sample: lung

Figure S2. |The effect of GBFXD on RAF/MEK/ERK signaling pathway. Western blotting was used to detect the relative protein expressions of P-RAF/RAF, P-MEK/MEK, and P-ERK/ERK.

3). Intra-Pancreatic Insulin Nourishes Cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?. The American Journal of Chinese Medicine, 2020 (PubMed: 32468825) [IF=5.7]

Application: WB Species: Mice Sample: tumors tissue

Figure 4. See the legend of Fig. 3 for study design. (A, B) t-Akt and p-Akt results from the sub-studies that involved PGG (A) and EGCG (B). (C, D) t-MEK and p-MEK results from the sub-studies that involved PGG (C) and EGCG (D). (E, F) t-ERK1/2 and p-ERK1/2 results from the sub-studies that involved PGG (E) and EGCG (F). β-Actin was used as a loading control. The blotting data are derived from representative tumors. The histograms include data from all tumors. *p < 0:05.

4). Wenshen-Jianpi prescription, a Chinese herbal medicine, improves visceral hypersensitivity in a rat model of IBS-D by regulating the MEK/ERK signal pathway. Frontiers in Pharmacology, 2022 (PubMed: 36210803) [IF=5.6]

Application: WB Species: Rat Sample: colon tissues

FIGURE 7 Effect of WJP on the relative expression of mRNA of MEK1, MEK2, ERK1, and ERK2 and the relative expression of protein of p-MEK1/2, p-ERK1, and p-ERK2 in the colon in the four groups. (A) The relative expression of mRNA of MEK1, MEK2, ERK1, and ERK2. (B) The relative expression of protein of p-MEK1/2. (C) The relative expression of protein of p-ERK1 and p-ERK2. (D) Western blot analysis. *p < 0.05; **p < 0.01, versus the control group. # p < 0.05; ## p < 0.01, versus the model group. ▲ p < 0.05; ▲▲ p < 0.01, versus the positive drug group.

5). Loganin alleviates sepsis-induced acute lung injury by regulating macrophage polarization and inhibiting NLRP3 inflammasome activation. International Immunopharmacology, 2021 (PubMed: 33744777) [IF=5.6]

Application: WB Species: Mice Sample: lung tissues

Fig. 5. Loganin inhibits ERK and NF-κB signaling in sepsis-induced ALI mice. (A) The levels of pro-inflammatory cytokines TNF-α and IL-6 in BALF were measured by ELISA assay. (B) The expression of Bcl-2 and Bcl-xl were detected by western blotting. (C) The expression of MEK, p-MEK (Ser217/ Ser221), ERK, p-ERK (Thr202/Tyr204), IKK-α/β, p-IKK-α/β (Ser180/Ser181), IκB-α, p-IκB-α (Ser32/36), NF-κB p65 (cytoplasm), NF-κB p65 (nucleus) were determined by western blotting. Data were shown as means ± SD. n = 6. *p < 0.05 vs. sham. #p < 0.05 vs. CLP. ERK, extra-cellular signal-regulated kinase; NF-κB, nuclear factor-kappa B; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; BALF, bronchoalveolar lavage fluid; CLP, cecal ligation and puncture.

6). β-Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Frontiers in Pharmacology, 2021 (PubMed: 34512326) [IF=5.6]

Application: WB Species: Rat Sample:

FIGURE 5 Effects of β-PAE on AQP3 expression and cAMP/PKA/CREB signaling pathway-related proteins. (A,B) AQP3 expression; (C,D) VIP, VIPR2, cAMP and PKA expression; (E,F) MEK1/2, p-MEK1/2, ERK, p-ERK, p-p38, p38, MSK1, p-MSK1, CREB, p-CREB, and P300/CBP expression. Data are shown as mean ± SD (n = 3). # p < 0.05, ## p < 0.01 versus control group; * p < 0.05, ** p < 0.01 versus 5-FU group.

7). l-Theanine attenuates neointimal hyperplasia via suppression of vascular smooth muscle cell phenotypic modulation. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2020 (PubMed: 32402912) [IF=5.6]

Application: WB Species: Rat Sample: VSMCs

Fig. 5. L-Theanine inhibited activation of ERK1/2 but not STAT3 induced by PDGF-BB and AngII in VSMCs. (a, c) VSMCs were stimulated with PDGF-BB or AngII for the indicated times with or without L-theanine (200 μM). The protein levels of phospho-ERK1/2, ERK, phospho-STAT3, STAT3 were determined using western blot analysis. For (a), *P(5 min)=0.034, *P(10 min)=0.028, **P(30 min)=0.002, compared to the control group; for (c), *P(5 min)=0.041, **P(10 min)=0.008, **P(15 min)=0.008, **P(30 min)=0.016, compared with the control group. ***Pb.001, compared with control group; ns, no significance. (b, d) VSMCs were pretreated with L-theanine (0, 100, 200, 400 μM) for 1 h and then stimulated with PDGF-BB (20 ng/ ml) or AngII (100 nM) for 10 min. The protein levels of phospho-ERK1/2, ERK, phospho-STAT3, STAT3 were determined by using western blot analysis. For (b), **P(L-The 100 μM)= 0.004, compared with the PDGF-BB group; for (d), *P(L-The 100 μM)=0.024, **P(L-The 200 μM)=0.003, compared with the AngII group. ###Pb.001 compared with control group; ***Pb.001, compared with PDGF-BB or AngII group; ns, no significance. Data of 3 independent experiments performed in duplicates are presented as mean±S.E.M. Data were analyzed by two-way ANOVA (a, c) and one-way ANOVA (b, d) with Fisher's LSD test.

8). Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer. Biomedical Journal, 2023 (PubMed: 35091088) [IF=5.5]

Application: WB Species: Human Sample: HCT116 and SW480 cells

Fig. 4. Circ_0011385 silencing suppressed CRC development by interacting with miR-330-3p. (A and B) The effect of miR-330-3p inhibitor on miR-330-3p expression was determined by qRT-PCR in HCT116 and SW480 cells. (C–E) The impacts between circ_0011385 silencing and miR-330-3p inhibitor on the proliferation of HCT116 and SW480 cells were unveiled by MTT assay and cell colony formation assay. (F, I and J) Flow cytometry analysis was utilized to illustrate the effects between circ_0011385 silencing and miR-330-3p inhibitor on the apoptosis and cell cycle of HCT116 and SW480 cells. (G and H) Wound-healing and transwell assays were performed to reveal the influences between circ_0011385 absence and miR-330-3p inhibitor on the migration and invasion of HCT116 and SW480 cells, respectively. (K and L) Western blot assay was conducted to determine the influences between circ_0011385 downregulation and miR-330-3p inhibitor on the protein expression of CDK1 and Cyclin D1 in HCT116 and SW480 cells.

9). Optimized new Shengmai powder ameliorates myocardial fibrosis in rats with heart failure by inhibition of the MAPK signaling pathway. Journal of ethnopharmacology, 2024 (PubMed: 37739104) [IF=5.4]

Application: WB Species: Rat Sample:

Fig. 7. Effects of ONSMP on ERK1/2 signaling pathway. (A) Representative western blotting bands of p-RAS, RAS, p-RAF, RAF, p-MEK1/2, MEK1/2, p-ERK1/2, ERK1/2, p-ELK, ELK, and c-Fos in the myocardium, with vinculin as internal reference. (B–G) Statistical graphs of p-RAS/RAS, p-RAF/RAF, p-MEK1/2/MEK1/2, p-ERK1/2/ERK1/2, p-ELK/ELK, and c-Fos (n = 3). Data are presented as mean ± SEM. nsP > 0.05; ▲▲P < 0.01 vs the sham; **P < 0.01 vs the model; #P < 0.05, ##P < 0.01 vs the ONSMP-L; ※P < 0.05, ※※P < 0.01 vs the ONSMP-M.

10). Mechanisms of pancreatic tumor suppression mediated by Xiang-lian pill: An integrated in silico exploration and experimental validation. JOURNAL OF ETHNOPHARMACOLOGY, 2022 (PubMed: 35931303) [IF=5.4]

Application: WB Species: Mouse Sample:

Fig. 6. XLP suppressed pancreatic tumor growth of tumor-bearing mice. (A) Tumors of mice in different groups treated with different doses of XLP; (B) Tumor weights among different groups; (C) Tumor volume increased over time; (D) HE staining of mouse liver and kidney tissues; (E) Mouse body weight over time; (F) Tumor pathology among four groups under microscopy (HE, 200 × ), and the expression of Ki-67, PTGS2 and PTGS1 among four groups (IHC, 400 × ); (G) Quantitation of the IHC positive area of Ki-67, PTGS2 and PTGS1 in the tumor tissues of four groups (n = 8 each group, each dot represents one sample); (H) The expression of PTGS1 and PTGS2, the phosphorylation of MEK and ERK among four groups by immunoblotting; (I) Statistical analysis of the immunoblotting results. * denotes p < 0.05, ** p < 0.01 and *** p < 0.001 when compared with the control group; # denotes p < 0.05, ## p < 0.01 and ### p < 0.001 when compared with the 0.78 g/kg XLP group.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.

Phospho-MEK1/2 (Ser218+Ser222/Ser222+Ser226) Antibody - #AF8035

产品推荐

相关下载

MS Report

HPLC Report

MSDS

说明书

COA